NI Superintendent Pharmacist Issued Warning After Failing to Maintain Controlled Drug Records
Date of Decision: December 8, 2022
Registrant's Role: Pharmacist
Allegations:
- Failure to record the receipt of Schedule 1 and 2 controlled drugs in the Controlled Drug Register.
- Failure to record the supply of Schedule 1 and 2 controlled drugs in the Controlled Drug Register.
- Failure to comply with the pharmacy’s Standard Operating Procedure (SOP) for controlled drug record keeping.
Outcome: Warning with a finding of current impairment
GPhC Standards Breached:
- Standard 1 – Always put the patient first
- Standard 2 – Provide a safe and quality service
- Standard 3 – Act with professionalism and integrity
Case Summary
Allegations
The case against the registrant, a superintendent pharmacist and director of Dunmore Pharma Ltd, centred on extensive breaches of controlled drug regulations and internal standard operating procedures. Between April 2020 and July 2021, the registrant failed to ensure that Schedule 1 and 2 controlled drugs—including potent opioids such as morphine, fentanyl, and oxycodone—were properly recorded in the pharmacy’s Controlled Drug Register. These failures occurred on at least 91 occasions over a sustained period, highlighting systemic issues rather than isolated incidents.
Specifically, the allegations detailed:
Continue Reading the Full Case
This case was published more than two weeks ago. A premium subscription is required to read the complete case summary.
- Full allegations considered by the GPhC/PSNI
- Panel findings and reasoning
- Outcome of the investigation
- Sanctions considered and imposed on the Pharmacist
- Key professional learning points
Original Case Document
The original determination document is available to registered users.